MIBC: Bladder sparing warrants careful consideration
“I think it’s time to realize that there are other options besides cystectomy, and that the other options should at least be discussed and entertained,” says Alexandre Zlotta, MD, PhD, in this video.
Bladder-sparing treatments, including trimodal therapy, should be carefully considered as alternatives to cystectomy in patients with muscle-invasive bladder cancer (MIBC).
That was the key take-home message of Alexandre Zlotta, MD, PhD, of Mount Sinai Hospital and the University of Toronto, who spoke at the Society of Urologic Oncology annual meeting in Phoenix.
In this video, Dr. Zlotta talks to Urology Times about involving MIBC patients in the treatment decision, how to monitor patients undergoing bladder preservation, and the importance of a specialized, multidisciplinary center in a bladder preservation program.
“I think it’s time to realize that there are other options besides cystectomy, and that the other options should at least be discussed and entertained,” Dr. Zlotta said.
Dr. Zlotta is a consultant for Ferring, Sanofi-Aventis, 3D Biopsy, and Sanofi-Pasteur.
Ra223 plus SABR does not delay progression of oligometastatic HSPC
October 3rd 2024"The addition of radium-223 to SABR metastasis-directed therapy in low-volume bone-metastatic hormone-sensitive prostate cancer does not delay progression of disease in the RAVENS study," said Ana Kiess, MD, PhD.
